Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LYMPHOSEEK KIT vs AMNESTROGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Technetium Tc-99m tilmanocept is a receptor-targeted radiopharmaceutical that binds to the mannose-binding protein (CD206) expressed on macrophages and dendritic cells within lymph nodes. It is used for lymphatic mapping and sentinel lymph node detection.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.
For lymphoscintigraphy to assist in the localization of sentinel lymph nodes draining a primary tumor site in patients with breast cancer or melanoma.
Treatment of moderate to severe vasomotor symptoms due to menopause,Treatment of vulvar and vaginal atrophy due to menopause,Prevention of postmenopausal osteoporosis,Estrogen replacement therapy in female hypogonadism,Palliative treatment of advanced breast cancer in selected postmenopausal women,Palliative treatment of advanced prostate cancer
Pre-dose: 20 mcg (0.5 m L) intradermally followed by 0.5 m L subcutaneously of the same dose 15-30 minutes later. Imaging: After 24 hours, 2 m L (20 mcg) subcutaneously.
1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily
6 hours (physical half-life of technetium-99m). Effective half-life is approximately 6 hours, allowing imaging up to 24 hours post-injection.
Terminal elimination half-life is 13-18 hours; steady-state achieved after 5-7 days.
Technetium Tc-99m tilmanocept is not metabolized; it is cleared from the injection site via the lymphatic system and excreted renally.
Hepatic metabolism via cytochrome P450 enzymes (CYP3A4 and others); undergoes enterohepatic recirculation.
Renal: 100% (as technetium-99m pertechnetate). No biliary or fecal elimination.
Primarily renal (90-95%) as glucuronide and sulfate conjugates; biliary/fecal elimination accounts for <5%.
Negligible (<5%), primarily to albumin.
98% bound primarily to albumin and sex hormone-binding globulin (SHBG).
Approximately 0.2 L/kg, indicating distribution within extracellular fluid.
1.0-1.5 L/kg; indicates extensive tissue distribution and binding.
Not applicable (administered parenterally).
Oral: 2-10% due to first-pass metabolism; IM: 100%; Transdermal: 5-15%; Vaginal: 5-25%.
No dose adjustment required based on GFR, but ensure adequate hydration.
No specific dose adjustment required; use with caution in severe impairment (e GFR <30 m L/min/1.73m²) due to potential fluid retention
No specific guidelines available; use with caution in severe hepatic impairment.
Contraindicated in Child-Pugh class B and C; for class A, use lowest effective dose with monitoring
Not established; safety and efficacy in pediatric patients have not been studied.
Not indicated for pediatric use; safety and efficacy not established
No specific dosage adjustment; monitor for adverse effects as elderly may have reduced immune response.
Use lowest effective dose for shortest duration; increased risk of stroke, dementia, and breast cancer; consider alternative therapies
This drug does not have a black box warning.
Estrogens increase the risk of endometrial cancer in postmenopausal women with an intact uterus. Estrogen-progestin therapy increases the risk of cardiovascular events, breast cancer, and probable dementia. Estrogen-alone therapy increases the risk of stroke and deep vein thrombosis.
Risk of hypersensitivity reactions including anaphylaxis.,Not for intrathecal administration.,Radiation exposure risk.
Cardiovascular disorders (stroke, MI, thromboembolism), malignant neoplasms (endometrial cancer, breast cancer), probable dementia (use >65 years), gallbladder disease, hypercalcemia, visual abnormalities, elevated blood pressure, hereditary angioedema, hypertriglyceridemia, fluid retention, hypothyroidism, exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, SLE, hepatic hemangiomas, and conditions aggravated by fluid retention.
Known hypersensitivity to tilmanocept or any component of the formulation.
Known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer (except selected patients), known or suspected estrogen-dependent neoplasia, active DVT/PE or history of thromboembolic disorders, known protein C, protein S, or antithrombin deficiency, known thrombophilic disorders, active or recent arterial thromboembolic disease (e.g., stroke, MI), known liver impairment or disease, known hypersensitivity to any ingredient.
No known food interactions. No dietary restrictions required.
Grapefruit and grapefruit juice may increase estrogen levels; avoid large amounts. No significant food interactions reported but take with or without food consistently to maintain stable absorption.
Lymphoseek is not systemically absorbed; the radiolabeled tracer (technetium Tc 99m tilmanocept) is administered subcutaneously. No fetal radiation exposure occurs at recommended doses. However, if administered intravenously, radiation exposure to the fetus could occur. No teratogenic effects are expected from the non-radioactive component (tilmanocept). Pregnancy category not assigned by FDA for diagnostic radiopharmaceuticals. Use only if clearly needed.
First trimester: Increased risk of congenital anomalies including cardiovascular defects and neural tube defects. Second and third trimesters: Risk of urogenital tract abnormalities, feminization of male fetus, and potential long-term reproductive effects. Use contraindicated in pregnancy.
It is unknown whether tilmanocept is excreted in human milk. Because of the low dose and local administration, systemic exposure is minimal. However, to minimize radiation exposure to the nursing infant, temporary cessation of breastfeeding for 4-6 hours after administration is recommended. M/P ratio not available.
Contraindicated during breastfeeding. Amnestrogen is excreted in breast milk; M/P ratio unknown. Potential for serious adverse effects in nursing infants including hormonal disruption.
No dose adjustment necessary. The administered activity of technetium Tc 99m tilmanocept is typically 18.5-74 MBq (0.5-2.0 m Ci) regardless of pregnancy. Pharmacokinetic changes in pregnancy are not expected to require dose modification due to local subcutaneous administration.
Not applicable as drug is contraindicated in pregnancy. No dose adjustment recommended due to avoidance of use.
Lymphoseek (technetium Tc 99m tilmanocept) is a receptor-targeted radiotracer for sentinel lymph node mapping. Administer intradermally, subcutaneously, or peritumorally. Optimal imaging time: 15-60 min post-injection. Can be used in patients with penicillin allergy as it contains no penicillin. Ensure patient is not pregnant or lactating. May cause injection site reactions.
Amnestrogen (estrogen-progestin combination) is used for hormone replacement therapy. Monitor for thromboembolic events; avoid in patients with history of DVT/PE. Use lowest effective dose for shortest duration. Not for use in pregnancy; contraindicated in breast cancer. May increase risk of endometrial cancer if used without progestin in women with intact uterus.
This is a radioactive dye used to find lymph nodes during surgery.,You will receive a small injection near the tumor site.,The procedure is generally safe, but inform your doctor if you are pregnant or breastfeeding.,You may experience mild pain, redness, or swelling at the injection site.,No special dietary restrictions are needed before the procedure.
Take exactly as prescribed; do not skip doses.,Report immediately any signs of blood clots: sudden leg pain, chest pain, shortness of breath, or vision changes.,Avoid smoking while on this medication; increases clot risk.,Do not use during pregnancy; if pregnancy occurs, stop and contact doctor.,Regular breast exams and mammograms are recommended.,May cause nausea; take with food or at bedtime.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LYMPHOSEEK KIT vs AMNESTROGEN, answered by our medical review team.
LYMPHOSEEK KIT is a Radiopharmaceutical Diagnostic Agent that works by Technetium Tc-99m tilmanocept is a receptor-targeted radiopharmaceutical that binds to the mannose-binding protein (CD206) expressed on macrophages and dendritic cells within lymph nodes. It is used for lymphatic mapping and sentinel lymph node detection.. AMNESTROGEN is a Estrogen that works by Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LYMPHOSEEK KIT and AMNESTROGEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LYMPHOSEEK KIT is: Pre-dose: 20 mcg (0.5 m L) intradermally followed by 0.5 m L subcutaneously of the same dose 15-30 minutes later. Imaging: After 24 hours, 2 m L (20 mcg) subcutaneously.. The standard adult dose of AMNESTROGEN is: 1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LYMPHOSEEK KIT and AMNESTROGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LYMPHOSEEK KIT is classified as Category C. Lymphoseek is not systemically absorbed; the radiolabeled tracer (technetium Tc 99m tilmanocept) is administered subcutaneously. No fetal radiation exposure occurs at recommended d. AMNESTROGEN is classified as Category C. First trimester: Increased risk of congenital anomalies including cardiovascular defects and neural tube defects. Second and third trimesters: Risk of urogenital tract abnormalitie. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.